Where is Oncogeni located?

Oncogeni is headquartered in Stratford upon avon, United Kingdom. It is registered at 85 GREAT PORTLAND STREET,FIRST FLOOR,LONDON,ENGLAND,W1W 7LT.

How many employees does Oncogeni have?

As of May 31, 2022, the latest employee count at Oncogeni is 1.

Where does Oncogeni rank among its competitors?

Oncogeni ranks 2957th amongst 3337 active competitors, of which 1138 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Oncogeni?

Oncogeni's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Oncogeni - 2026 Company Profile, Team, Competitors & Financials

Company Details

Developer of RNA-based therapeutics for cancer treatment. It offers drugs that specialize in small interfering RNA and mesodermal killer cells that help in treating multiple cancers.

Website: oncogeni.com
Registered Address: 85 GREAT PORTLAND STREET,FIRST FLOOR,LONDON,ENGLAND,W1W 7LT

Key Metrics

Founded Year

2019

Location

Stratford upon avon, United Kingdom

Stage

Acquired

Ranked

2957^th among 3337 active competitors

Employee Count

1 as on May 31, 2022

Similar Companies

Jazz Pharmaceuticals & 3037 more

Exit Details

Acquired by The Nation Trust Holding (Mar 10, 2025)

View Oncogeni's full profile

Oncogeni is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ONCOGENI LTD CIN: 12021845 , United Kingdom, Active	May 28, 2019	-	1 (As on May 31, 2022)

Oncogeni got acquired by The Nation Trust Holding on Mar 10, 2025 at an acquisition amount of $*****.

Click here to take a look at Oncogeni's acquisition in detail

Oncogeni has not raised any funding rounds yet.

The founders of Oncogeni is Martin Evans. Ajan Reginald is the CEO of Oncogeni.

Here are the details of Oncogeni's key team members:

Martin Evans: Founder of Oncogeni and founder of 1 other company. They serve on the board of 1 company.
Ajan Reginald: CEO of Oncogeni. They serve on the board of 1 company.

Oncogeni's Board of Directors

Oncogeni's board has 2 active members. Ajan Reginald is part of team and Stephen Paul West is independent board member.

Here is the list of Oncogeni's board of directors:

Name	Type	Representing	Status	Duration
rhjyfkv	Team	-	Past	2y 4m
nesdaif	Team	-	Current	8y 7m
Stephen Paul West	Independent board member	-	Current	3y 8m
uooqloy	Independent board member	-	Past	5y 9m

View details of Oncogeni's Founder profiles and Board Members

Oncogeni's employee count trend

Oncogeni has 1 employees as of May 22. Here is Oncogeni's employee count trend over the years:

Uncover Oncogeni's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oncogeni include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Oncogeni, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
2957th	Oncogeni 2019, Stratford upon avon (United Kingdom), Acquired	Developer of RNA-based therapeutics for cancer treatment	-	-	21/100